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Cells released from primary tumors seed metastases
to specific organs by a nonrandom process, implying
the involvement of biologically selective mecha-
nisms. Based on clinical, functional, and molecular
evidence, we show that the cytokine TGFb in the
breast tumor microenvironment primes cancer cells
for metastasis to the lungs. Central to this process
is the induction of angiopoietin-like 4 (ANGPTL4) by
TGFb via the Smad signaling pathway. TGFb induc-
tion of Angptl4 in cancer cells that are about to enter
the circulation enhances their subsequent retention
in the lungs, but not in the bone. Tumor cell-derived
Angptl4 disrupts vascular endothelial cell-cell junc-
tions, increases the permeability of lung capillaries,
and facilitates the trans-endothelial passage of
tumor cells. These results suggest a mechanism for
metastasis whereby a cytokine in the primary tumor
microenvironment induces the expression of another
cytokine in departing tumor cells, empowering these
cells to disrupt lung capillary walls and seed pulmo-
nary metastases.
INTRODUCTION
The identification of metastasis genes and mechanisms is
essential for understanding the basic biology of this lethal condi-
tion and its implications for clinical practice (Fidler, 2003; Gupta
and Massague´, 2006). The predisposition of primary tumors to
selectively invade different organs has been long recognized
(Paget, 1889). Recent work has functionally identified and clini-
cally validated sets of genes whose overexpression in breast
cancer cells confers a selective advantage for the colonization
of bones (Kang et al., 2003b; Lynch et al., 2005) or lungs (Minn
et al., 2005). There is also the possibility that the microenviron-66 Cell 133, 66–77, April 4, 2008 ª2008 Elsevier Inc.ment of a primary tumor may influence the fate of cancer cells
that escape from this tumor. Among the factors in the tumor
microenvironment that might play such a role, we chose to focus
on the cytokine TGFb, which modulates tumor progression in
various experimental systems (Bierie and Moses, 2006; Dumont
and Arteaga, 2003; Siegel and Massague´, 2003).
TGFb is a multifunctional cytokine with diverse effects on
virtually all cell types and with key roles during embryo develop-
ment and tissue homeostasis (Massague´ et al., 2000). It regu-
lates the production of microenvironment sensors and modula-
tors, including cytokines, extracellular matrix components, and
cell-surface receptors. Additionally, TGFb has potent inhibitory
effects on cell proliferation, and, as such, it can deter tumor
growth (Bierie and Moses, 2006; Dumont and Arteaga, 2003;
Siegel and Massague´, 2003). Within the tumor microenviron-
ment, TGFb is produced by myeloid cells, mesenchymal cells,
and the cancer cells themselves, as a natural response to the
hypoxic and inflammatory conditions that occur during tumor
progression. The TGFb receptors, which are membrane serine/
threonine protein kinases, and their substrates, the Smad tran-
scription factors, are tumor suppressors that frequently suffer
inactivation in gastrointestinal, pancreatic, ovarian, and hepato-
cellular cancinomas and subsets of gliomas and lung adenocar-
cinomas (Bierie andMoses, 2006; Levy and Hill, 2006). However,
in breast carcinoma, glioblastoma, melanoma, and other types
of cancer, selective losses of growth inhibitory responses often
accrue through alterations downstream of Smad, leaving the
rest of the TGFb pathway operational and open to co-option
for tumor-progression advantage (Massague´ and Gomis,
2006). Low-level expression of TGFb receptors in the ER-nega-
tive (ER) breast tumors is associated with better overall out-
come (Buck et al., 2004), whereas overexpression of TGFb1 is
associated with a high incidence of distant metastasis (Dalal
et al., 1993). Studies in mouse models of breast cancer have im-
plicated TGFb in the suppression of tumor emergence (Bierie
and Moses, 2006; Siegel and Massague´, 2003), but also in the
induction of epithelial-mesenchymal transitions and tumor
invasion (Thiery, 2002; Welch et al., 1990), the production of
Figure 1. The TBRS Associates with Breast Cancer Metastasis in Humans
(A) The indicated epithelial cell lines were incubated for 3 hr with TGFb, and then total RNA was subjected to microarray analysis. The heat map represents the
change in expression levels of the 153 genes within the TBRS.
(B) TBRS status was assessed in a MSK/EMC cohort of 368 primary breast cancer tumors with known lung or bone metastatic outcomes. Red denotes a strong
correlation between individual tumor gene-expression profiles and the TBRS, while blue indicates no correlation. Estrogen receptor a (ER) expression status is
also indicated. Blue and red marks above the heat map indicate tumors that at any time developed bone or lung metastases, respectively.
(C) Kaplan-Meier curves representing the probability of cumulative lung (left panel) or bone (right panel) metastasis-free survival for this cohort. Tumors are cat-
egorized according to their TBRS and ER status. The P values for the ER-negative tumor comparisons are shown.
(D) Hierarchical clustering was performed on the MSK/EMC cohort with the indicated pathological and genomicmarkers including the TBRS, the lungmetastasis
signature (LMS), the wound response signature (Wound), the 70-gene prognosis signature (70-gene), size (Size > 2cm), the basal molecular subtype (Basal), and
the ER status. Red marks above the map indicate tumors that developed lung metastasis.
(E) Lungmetastasis-free survival restricted to patients with ER-negative tumors. Patients were categorized according to their TBRS and LMS status. P values are
shown for the LMS+ tumor comparisons.osteoclast-activating factors in the bone metastasis microenvi-
ronment (Kang et al., 2003b; Mundy, 2002), and the context-
dependent induction of metastasis (Dumont and Arteaga,
2003; Siegel and Massague´, 2003). Thus, the effects of TGFb
on breast cancer progression in mouse models are as profound
as they are disparate, making it difficult to discern from these
models the role that TGFb may be playing in human breast
cancer.
To investigate the contextual role of the TGFb pathway in
human cancer and the mechanism by which TGFbmay instigate
metastasis, we based our present work on the weight of clinical
evidence and the use of a bioinformatic tool that classifies
tumors based on the status of their TGFb transcriptional readout.
Applying this tool to a wealth of clinically annotated samples and
gene-expression data sets, we made the surprising observation
that TGFb activity in primary breast tumors is associated with an
increased propensity of these patients to develop lung metasta-
sis but not bone metastasis. This phenomenon implies a biolog-
ically selective TGFb-dependent mechanism that favors tumortargeting of the lungs. We identify this mechanism based on
ANGPTL4 as a critical TGFb target gene, whose induction in can-
cer cells in the primary tumor primes these cells for disruption of
lung capillary endothelial junctions to selectively seed lung
metastasis.
RESULTS
Development of a TGFb Response
Bioinformatics Classifier
In order to investigate the role of TGFb in cancer progression, we
set out to develop a bioinformatic classifier that would identify
human tumors containing a high level of TGFb activity. A gene-
expression signature typifying the TGFb response in human
epithelial cells was obtained from transcriptomic analysis of
four human cell lines (Figures 1A and S1). These cell lines include
HaCaT keratinocytes, HPL1 immortalized lung epithelial cells,
MCF10A breast epithelial cells, and MDA-MB-231 breast carci-
noma cells. The cells were treated with TGFb1 for 3 hr in order toCell 133, 66–77, April 4, 2008 ª2008 Elsevier Inc. 67
capture direct TGFb gene responses (Kang et al., 2003a) and
resulted in a 153-gene TGFb response signature (TBRS) (174
probe sets; Table S1). When applied to metastatic lesions
extracted frombones, lungs and other sites representing the nat-
ural metastatic spectrum of human breast cancer, the TBRS
classifier identified TGFb activity in a 38/67 of these samples
(Table S2), which is in agreement with previous observations of
activated Smad in a majority of human bone metastasis samples
(Kang et al., 2005).
TGFb Activity in Primary Breast Tumors Is Selectively
Linked to Lung Metastasis
We applied the TBRS classifier to a series of primary breast car-
cinomas that were analyzed on the same microarray platform
(Minn et al., 2005, 2007; Wang et al., 2005). This series includes
82 tumors collected at Memorial Sloan-Kettering Cancer Center
(MSK cohort) and 286 tumors from the Erasmus Medical Center
(EMC cohort). Both cohorts comprised a mix of breast cancer
subtypes, with tumors in the MSK cohort being more locally
advanced than those in the EMC cohort (Minn et al., 2007). Out
of a combined total of 368 patients, 39 patients developed
lung metastases and 83 developed bone metastasis after a me-
dian follow-up of 10 years, with some patients developing
metastases in both sites (Figure 1B). TBRS+ tumors were simi-
larly distributed between estrogen receptor-positive (ER+) and
ER tumors (Figure 1B). Microarray analysis revealed that the
TBRS+ tumors expressed significantly higher mRNA levels for
TGFb1, TGFb2, and the latent TGFb-activating factor, LTBP1.
TBRS tumors had lower mRNA levels for type II TGFb receptor,
Smad3, and Smad4. The expression level of other TGFb
pathway components was the independent of TBRS status
(Figure S2).
TBRS status in ER+ tumors did not correlate with distant me-
tastasis. However, in ER tumors there was a striking associa-
tion between TBRS+ status and relapse to the lungs (Figure 1C).
This association was observed regardless of whether the tumor
ER status was assigned using the clinical pathology reports,
which are based on immunohistochemical analysis (Figures 1B
and 1C), or using a microarray probe level designation (Figures
S3A and S3B). No link was observed between TBRS status
and bone metastasis (Figures 1D and S3C) or liver metastasis;
a brain metastasis association did not attain statistical signifi-
cance (Figure S4). In univariate as well as multivariate analyses,
the expression level of TGFb pathway components was much
inferior to the TBRS at linking these tumors with metastasis out-
come (Table S3). These results indicate that TGFb activity in ER
breast tumors is selectively associated with lung metastasis.
Cooperation between TGFb and the Lung
Metastasis Signature
The association of TBRS with lung relapse prompted us to
search for links between the TBRS and a previously described
lung metastasis signature (LMS) (Minn et al., 2005). The LMS is
a set of 18 genes whose expression in ER tumors indicates
a high risk of pulmonary relapse in patients (Minn et al., 2007).
Several of these genes have been validated as mediators of
lung metastasis (Gupta et al., 2007a, 2007b; Minn et al., 2005).
The TBRS+ subset of ER tumors partially overlapped the68 Cell 133, 66–77, April 4, 2008 ª2008 Elsevier Inc.LMS+ subset (Figure 1D). Remarkably, tumors that were positive
for both the TBRS and LMS were associated with a high risk of
pulmonary relapse, whereas single-positive tumors were not
(Figure 1E). Within poor-prognosis tumor subsets defined by
other features, such as size >2 cm, basal subtype gene-expres-
sion signature (Sorlie et al., 2003), 70-gene poor-prognosis sig-
nature (van de Vijver et al., 2002), or wound signature (Chang
et al., 2005), TBRS statuswas associatedwith risk of lungmetas-
tasis in nearly every case (Figure 1D). The TBRS performed inde-
pendently of these other prognostic features (Figure S5), as did
the LMS (Figure S6) (Minn et al., 2007).
TGFb Signaling in Mammary Tumors Enhances Lung
Metastatic Dissemination
The MDA-MB-231 cell line derived from the pleural fluid of
a patient with ER metastatic breast cancer evades TGFb
growth-inhibitory responses through alterations downstream of
Smads (Gomis et al., 2006). The lung metastatic subpopulation
LM2-4175 (henceforth LM2) was isolated by in vivo selection of
MDA-MB-231 cells in mice (Minn et al., 2005). We perturbed
the TGFb pathway in LM2 cells by overexpressing a kinase-
defective, dominant-negative mutant form of the TGFb type I
receptor (Weis-Garcia and Massague´, 1996) or by reducing the
expression of Smad4, which is an essential partner of Smad2
and Smad3 in the formation of transcriptional complexes (Mas-
sague´ et al., 2005). Using a SMAD4 short-hairpin RNA (shRNA)
(Kang et al., 2005), we reduced Smad4 levels by 80%–90% in
LM2 cells (Figure 2B).
Neither the dominant-negative TGFb receptor nor the Smad4
knockdown decreased mammary tumor growth as determined
by tumor volume measurements, or the extent of tumor cell
passage into the circulation, as determined by quantitative
(q)RT-PCR analysis of human GAPDH mRNA in blood cellular
fractions (Figures 2C and 2D). Tumors inoculated into the mam-
mary glands of immunocompromised mice and allowed to grow
to 300 mm3 were surgically removed and the emergence of
disseminated cells to the lungs after the mastectomy was deter-
mined (Figure 2A). Inactivation of TGFb signaling markedly in-
hibited the lung metastatic seeding of the tumors as determined
by quantitative bioluminescence imaging (Figures 2E and 2F,
insets) (Ponomarev et al., 2004) and histological examination
(Figure 2F). These results suggest that the canonical TGFb
pathway enhances mammary tumor dissemination to the lungs.
TGFb Primes Tumor Cells to Seed Lung Metastases
We wondered whether TGFb within the breast tumor microenvi-
ronment could endow tumor cells with the ability to seed the
lungs as these cells enter the circulation. To test this possibility,
we mimicked the exposure of tumor cells to TGFb by incubating
LM2 cells with TGFb for 6 hr prior to inoculation of these cells into
the tail veins of mice. Interestingly, this pretreatment with TGFb
significantly increased the lung colonizing activity of LM2 cells,
as determined by a higher retention of these cells in the lungs
24 hr after inoculation (Figure 3A). In this time frame LM2 cells
extravasate into the lung parenchyma (Gupta et al., 2007a). A
similar effect was observed when we carried out this experiment
with malignant cells (CN34.2A) obtained from the pleural fluid of
a breast cancer patient treated at MSKCC. The pretreatment
Figure 2. TGFb Signaling Enhances Mammary Tumor Dissemination to the Lungs
(A) Schematic of lung metastasis assay from an orthotopic breast cancer inoculation.
(B) Immunoblots using indicated antibodies were performed on whole-cell extracts from control, Smad4 knockdown, and Smad4-rescue LM2 cells.
(C) Mice injected with 5 3 105 cells into the fourth mammary fat pads were measured for tumor size at day 28. n = 14; error bars indicated standard error of the
mean (SEM).
(D) Blood from tumor-bearing mice was isolated and red blood cells lysed. RNA from the remaining cells was extracted for qRT-PCR. The presence of circulating
tumor cells was assessed as a function of human-specific GAPDH expression relative to murine b2-microglobulin, in 3 ml of mouse blood perfusate. n = 8; error
bars indicate SEM.
(E) Bioluminescent quantification of lung seeding elicited from orthotopically implanted breast tumors. Orthotopic tumors were grown to approximately 300mm3,
mastectomies were performed, and lung seeding was quantified using bioluminescence imaging 7 days later. n = 7–15; error bars indicated SEM; p values cal-
culated using the one-tailed unpaired t test.
(F) Representative bioluminescent images (inset) and lung histology of mice with the median value of bioluminescence in each experimental group in (D). Breast
cancer cells were stained with human vimentin.with TGFb increased the lung seeding activity of LM2 and
CN34.2A cells 3- and 5-fold, respectively (Figure 3B). The initial
advantage provided by a transient exposure to TGFb was
sustained but not expanded during the ensuing outgrowth of
metastatic colonies (Figure 3A and data not shown).
To investigate the selectivity of this lung metastasis-priming
effect, we tested the effect of TGFb preincubation on the estab-
lishment of bone metastases. LM2 cells have limited bone met-
astatic activity in addition to their high lung metastatic activity
(Minn et al., 2005). The pretreatment of LM2 cells with TGFb prior
to their inoculation into the arterial circulation did not increase the
ability of these cells to colonize the bone (Figure 3C). We also
tested the effect of TGFb on the metastatic seeding of an
MDA-MB-231 subpopulation (BoM-1833) that is highly meta-
static to bone (Kang et al., 2003b) and responsive to TGFb
(Kang et al., 2005). Preincubation of BoM-1833 cells with TGFbdid not increase their bone colonizing ability (Figure 3C) and
had no discernible effect on the early seeding of the bones
(Figure 3D). Thus, TGFb stimulation primes tumor cells for an
early step in lung metastasis but not bone metastasis, which is
concordant with the selective association of TBRS+ status in
primary tumors with risk of lung metastasis in clinical cohorts
(refer to Figure 1C).
The TBRS/LMS Gene ANGPTL4 Is a TGFb Target
in Breast Cancer
Given the convergenceof the TBRSand the LMS in linking human
primary tumors to risk of lung metastasis, we wondered whether
TGFbmay act by augmenting the activity of an LMS gene(s). The
LMS includes 15 candidate mediators of lung metastasis and 3
suppressors (Minn et al., 2005) (see Figure 4C). Interestingly,
the LMS genes ANGPTL4, which encodes the multifunctionalCell 133, 66–77, April 4, 2008 ª2008 Elsevier Inc. 69
Figure 3. TGFb Primes Tumor Cells for Metastatic Seeding of the Lungs
(A) LM2 cells and a clinically derived pleural effusion sample (CN34.2A) were pretreated with TGFb for 6 hr. LM2 (2 3 105) and CN34.2A (4 3 105) cells were
injected into the lateral tail vein, and lung colonization was analyzed by in vivo bioluminescence imaging.
(B) Bar graph represents 24 hr time-point measurements of the normalized photon flux from animals injected with either LM2 or CN34.2A cells. In vivo biolumi-
nescent mouse images shown are from representative animals. n = 7 for the LM2 experiment, while n = 6 for the CN34.2A experiment; error bars indicate SEM;
p values calculated using the one-tailed unpaired t test.
(C) Bone-colonization assays were performed by intracardiac injection of LM2 or BoM-1833 cells (33 104). Samples were pretreatedwith 100 pM of TGFb for 6 hr
and compared to an untreated control. Plot represents normalized photon flux from mouse hind limbs.
(D) Bar graphs represent 7-day time point analysis of the normalized photon flux from the mouse hind limbs. n = 8; error bars indicate SEM.factor angiopoietin-like 4 (Oike et al., 2004), and NEDD9, which
encodes an adaptor protein implicated in focal contact formation
andcellmotility (Kimet al., 2006),werepresent in theTBRS (Table
S1). An induction of ANGPTL4 by TGFbwas observed in four dif-
ferent epithelial cell types tested (Figure 4A). Moreover, among
ER tumors ANGPTL4 expression was significantly higher in
the TBRS+ tumors (median-centered intensity value = 1.07)
than in TBRS tumors (median value = 0.30).NEDD9 expression
was not different between these two groups (Figure 4B). TBRS+
andTBRS tumors in the ER+group showed a smaller difference
in ANGPTL4 expression (Figure S7).
To determine the effect of TGFb on individual LMS genes, we
used tumor cells isolated from pathological pleural fluids from
patients with ER and ER+ metastatic breast cancer. Lung me-
tastasis was diagnosed in six out of seven of these cases. All
samples were obtained from routine therapeutic procedures
and were used under institutionally approved protocols and
informed consent (Gomis et al., 2006). Carcinoma cells were iso-
lated from these samples using the epithelial cell-surface marker70 Cell 133, 66–77, April 4, 2008 ª2008 Elsevier Inc.EpCAM (Kielhorn et al., 2002). TGFb addition increased
ANGPTL4 expression between 2- and 12-fold in all metastatic
samples, and 16-fold in the LM2 cells, as determined by
qRT-PCR (Figure 4C).
None of the other LMS genes, NEDD9 included, was consis-
tently regulated by TGFb in this set of samples, with one excep-
tion: the transcriptional inhibitor of cell differentiation ID1 was
induced approximately 2-fold by TGFb in most samples
(Figure 4C). As a component of the LMS, ID1mediates tumor re-
initiation after ER cells enter the lung parenchyma (Gupta et al.,
2007b). This induction of ID1 by TGFb is interesting given the fact
that TGFb represses ID1 in untransformed breast epithelial cells
(Kang et al., 2003a). This switched responsiveness of ID1 is
consistent with the pattern of loss of TGFb growth-inhibitory re-
sponses in metastatic breast cancer cells (Gomis et al., 2006).
The induction of ANGPTL4 expression by TGFbwas observed
in all 13 malignant pleural cell samples tested, regardless of the
ER, progesterone receptor, or ERBB2 receptor status (Table 1).
Its induction by TGFb was rapid and lasted for 8 hr (Figure 4D).
Figure 4. The TBRS/LMS Gene ANGPTL4 Is a Smad-Dependent TGFb Target
(A) Microarray and qRT-PCR analysis for the four epithelial cell lines treated with TGFb. Fold change values for the TGFb induction of ANGPTL4 are indicated.
(B) Box-and-whisker plot comparing ANGPTL4 and NEDD9 TBRS-negative and -positive ER-negative tumors from the MSK/EMC cohorts. P value was calcu-
lated using the Wilcoxon rank sum test.
(C) TGFb-induced changes in the mRNA expression of LMS genes in a panel of clinically derived pleural effusion samples and LM2 cells. Cells were treated with
100 pM of TGFb for 3 hr and analyzed by qRT-PCR using primers for the indicated genes. ER status for each breast cancer patient is designated.
(D) LM2 breast cancer cells were treated with 100 pM of TGFb for the indicated lengths of time, and ANGPTL4mRNA levels were analyzed using qRT-PCR. n = 3;
error bars indicate standard deviation (SD).
(E) Treatment of LM2 (left panel) and pleural effusion-derived CN37 sample (right panel) with TGFb and the TGFb-receptor kinase inhibitor, SB431542. qRT-PCR
expression levels are shown relative to the untreated control sample. n = 3; error bars indicate SD.
(F) MDA-231, LM2 control, LM2-Smad4-depleted, and LM2-Smad4-rescue cell lines were treated with 100 pM TGFb for 3 hr. TGFb-induced fold changes of
ANGPTL4 were analyzed by qRT-PCR analysis. n = 3; error bars indicate SD.Addition of SB431542, an ATP analog inhibitor of the TGFb type I
receptor kinase (Laping et al., 2002), abolished the ANGPTL4 re-
sponse in LM2 and CN37 cells (Figure 4E). Smad4 knockdown
markedly inhibited the ANGPTL4 response to TGFb, whereas
a shRNA-resistantSMAD4 cDNA containing two silentmutations
in the shRNA-targeted sequence rescued this response
(Figure 4F). Among various cytokines that are typical of the tumor
microenvironment, TGFbwas the strongest inducer of ANGPTL4
in the MDA-MB-231 cells (Figure S8). Thus, ANGPTL4 induction
in metastatic breast cancer cells is mediated by the canonical
TGFb-receptor-Smad pathway.
ANGPTL4 Participates in TGFb Priming
for Lung Metastasis
To investigate whether ANGPTL4 participates in the prometa-
static effects of TGFb, we knocked down its expression in LM2cells by means of a shRNA (Figure 5A). This knockdown did
not decrease the ability of LM2 cells to grow asmammary tumors
(Figure 5B) and to pass into the circulation (Figure 5C). The inci-
dence of lymph-node metastases in LM2 tumor-bearing mice
was also not affected by ANGPTL4 knockdown (Figure 5D).
However, the dissemination to the lungs from orthotopically im-
planted LM2 tumors was decreased more than 10-fold by the
ANGPTL4 knockdown, and this decrease could be prevented
with the ANGPTL4-rescue construct (Figure 5E). ANGPTL4
knockdown did not decrease the residual bone metastatic
activity of LM2 cells (data not shown).
When orthotopically implanted, LM2 tumors accrue TGFb
activity that primes lung metastasis seeding (refer to
Figure 2D). We subjected the ANGPTL4 knockdown LM2 cells
to the ex vivo TGFb priming assay. Of note, the induction of
ANGPTL4 expression by TGFb was blunted but not completelyCell 133, 66–77, April 4, 2008 ª2008 Elsevier Inc. 71
Table 1. Clinical and Histological Staging of Malignant Pleural Effusion Samples, and Their ANGPTL4 Response to TGFb
ER Statusa PR Statusa ERBB2 Statusa Tumor Type Metastatis Sites ANGPTL4 mRNA +/ TGFb
CN19 + + + ductal Pl, Lu, LN 2.9
CN34 +  ++ ductal Pl, Lu, Bo, LN 3.8
CN37 + + ++ ductal Pl, Lu, LN, Br, Li 6.7
CN41 + + ++ ductal Pl, Lu?, Bo, Br, CW 8.7
CN43 + + + ductal Pl, Lu, Bo, Li 2.3
CN46   +++ ductal Pl, Bo, ST, LN 12.8
CN47 + + + lobular Pl, Lu, Li, LN, Ca, Co 2.8
CN90    ductal Pl, Lu, Bo, Li 24.7
BCN5 + + + ductal Pl, Lu, Bo, LN, Sc 9.5
BCN6 + + +++ ductal Pl, Lu, Bo, Li 10.9
BCN7 + + + ductal Pl, Lu, Bo, Li, LN, Ad 10.2
BCN8 +   lobular Pl, Bo, As, ST 3.0
BCN9    ductal Pl, LN 13.7
Pl, pleura; Lu, lung; Bo, bone; Br, brain; Sc, subcutaneous; LN, lymph nodes; Li, liver; Ad, adrenal; As, ascites; ST, soft tissue; Ca perinoteal
carcinomatosis; Co, colon; CW, chest wall.
a Status in primary tumor.eliminated in the knockdown cells (Figure 5F). This notwithstand-
ing, the knockdown of ANGPTL4 significantly blunted the prim-
ing effect of TGFb on lung seeding by LM2 cells (Figure 5G).
The constitutive overexpression of exogenous ANGPTL4 in
LM2 cells increased lung colonization by these cells
(Figure 5H). These results provide evidence that ANGPTL4
expression is necessary for the ability of TGFb to prime LMS+
breast cancer cells and sufficient for increasing seeding of the
lungs.
Angptl4 Mediates Endothelial Disruption
and Trans-Endothelial Tumor Cell Passage
The ability of TGFb to promote lung seeding through an induction
of ANGPTL4 suggested that this process may target an early
step in pulmonary metastasis. Extravasation, or the passage of
circulating tumor cells through the tight lung capillary endothelial
junctions, is an important initial step. We, therefore, investigated
whether Angptl4 might affect endothelial cell layers in a manner
that would facilitate the passage of tumor cells across endothe-
lia. HUVEC human vascular endothelial cells were allowed to
grow to form tight monolayers on tissue-culture dishes, and at
this point the monolayers were exposed to media containing
human recombinant Angptl4 or no addition (Figure 6A), or media
conditioned by control LM2 cells or by cells overexpressing
Angptl4 (Figure 6B). In both cases Angptl4 caused an acute dis-
ruption of endothelial cell-cell junctions. Staining with antibodies
against the tight junction component zonula occludens 1 (ZO-1),
against the adherens junction component b-catenin, or staining
of the actin cytoskeleton with phalloidin (Dejana, 2004) revealed
that the monolayer integrity was dramatically perturbed by
Angptl4 (Figures 6A and 6B).
GFP-labeled MDA-MB-231 cells either expressing a control
vector or expressing Angptl4 were inoculated into NOD/SCID
mice. One day post inoculation, the animals were injected with
a rhodamine-conjugated dextran, in order tomeasure vessel per-
meability. The lungs were then extracted and analyzed for re-72 Cell 133, 66–77, April 4, 2008 ª2008 Elsevier Inc.tained rhodamine using fluorescent microscopy. No rhodamine
signal was present in the lungs of mice that were not inoculated
with cancer cells (data not shown). In inoculated animals, how-
ever, diffuse areas of rhodamine signal surrounded the cancer
cells that lodged in the lungs (Figure 6C). Cells overexpressing
Angptl4 showed a 3-fold increase in surrounding rhodamine sig-
nal, as determinedbyquantitative analysis of the fluorescent area
(Figures 6D andS9). To test the effect of Angptl4 on cell migration
across an endothelial layer, endothelial monolayers were set on
trans-well tissue culture inserts. LM2 cells overexpressing
Angptl4 passed twice as efficiently through these layers into the
lower chamber of the trans well compared to control LM2 cells
(Figure 6E). Collectively, these data demonstrate that Angptl4
disrupts the integrity of vascular endothelial cell layersboth in vitro
and in the lungs, facilitating the passage of breast cancer cells.
DISCUSSION
Primary tumor microenvironments may promote metastasis by
selecting for highly invasive and resistant cancer cell phenotypes
(Bernards and Weinberg, 2002) and systemically fostering the
mobilization of marrow-derived progenitor cells (Kaplan et al.,
2005). The ability to subsequently colonize distant organs
depends on the organ-colonizing faculties of disseminated
tumor cells as well as on certain permissive conditions that
may be present in the otherwise restrictive microenvironment
of target organs (Gupta and Massague´, 2006). The present
results suggest a distinct mechanism for the colonization of
a distant organ, one that relies on a stimulus in the primary tumor
microenvironment to enhance the ability of departing tumor cells
to seed the lungs (Figure 6F).
Angptl4 as an Inhibitor on Endothelial Integrity
that Mediates Lung Metastasis Seeding
Angptl4 is expressed in the liver, adipose tissue, and placenta, as
well as in ischemic tissues. It was identified in a search for new
Figure 5. Angptl4 Mediates TGFb Priming for Mammary Tumor Dissemination to the Lungs
(A) Secreted Angptl4 protein levels in the control, ANGPTL4 knockdown, or ANGPTL4-rescue LM2 cells were analyzed by ELISA. n = 3; error bars indicate SD.
(B) Tumor size measurements were taken frommice inoculated into the fourth mammary fat pads with 53 105 control, ANGPTL4 knockdown, or ANGPTL4-res-
cue LM2 cells. Tumor size was measured at day 28. n = 14; error bars indicated SEM.
(C) The presence of circulating tumor cells was assessed by qRT-PCR as a function of human-specificGAPDH expression relative to murine b2-microglobulin, in
3 ml of mouse blood perfusate. n = 10; error bars indicate SEM.
(D) Peri-aortic lymph node metastasis from indicated tumors was analyzed by ex vivo detection of luciferase activity. Positive bioluminescent signal in extracted
lymph nodes indicated presence of metastasized tumor cells.
(E) Photon flux measurements of breast cancer cells seeding the lung from orthotopically injected tumors as indicated. n = 13–15; error bars indicated SEM;
p values calculated using the one-tailed unpaired t test.
(F) ANGPTL4 mRNA levels were determined by qRT-PCR analysis in cells that were incubated for 6 hr with or without TGFb. n = 3; error bars indicate SD.
(G) Lung-colonization analysis was performed by injecting 23 105 cells into the lateral tail vein. Prior to injection, cells were treated as indicatedwith 100 pMTGFb
for 6 hr. Bar graphs represent 24 hr time-pointmeasurements of the normalized photon flux. n = 14–21; error bars indicate SEM; p values calculated using the one-
tailed unpaired t test.
(H) Normalized photon flux measurements from tail vein injected animals. Lung-colonization measurements were taken from animals injected with control or
Angptl4-overexpressing LM2 cells. n = 6; error bars indicate SEM; p values calculated using the one-tailed unpaired t test.members of the angiopoietin family of vascular regulators, and
independently in a search for targets of the PPAR family of met-
abolic response transcription factors (Oike et al., 2004). While
Angptl4’s role in lipid metabolism has been well characterized,
little is known about its role in vascular biology. Indeed, the
effects of angiopoietin-like proteins in experimental systems
are complex, at times acting as general endothelial cell survival
factors (Kim et al., 2000), modulating endothelial cell adhesion
(Cazes et al., 2006), or paradoxically stimulating (Hermann
et al., 2005; Le Jan et al., 2003) as well as inhibiting angiogenesis
(Ito et al., 2003). Chronic systemic secretion of Angptl4 from
a transgene expressed in muscle tissue in mice inhibited metas-
tasis by xenografted melanoma cells (Galaup et al., 2006). These
diverse responses are suggestive of a context, tissue-specific
activity of this multifaceted molecule.
ANGPTL4 is one of the top performing genes in the LMS with
a highly significant association with lung relapse (p < 0.000001)
(Minn et al., 2005). In the present work, we show that TGFb stim-
ulation sharply increased the expression of ANGPTL4, and we
have functionally validated ANGPTL4 as a mediator of breast
cancer lung metastasis. ANGPTL4 knockdown in LMS+ cells in-
hibits their ability to seed the lungs, and it does so without affect-
ing the growth of these cells as mammary tumors, their passage
into the circulation, or their invasion of lymph nodes. Angptl4antagonizes vascular endothelial tight junctions and adherens
junctions, and disrupts the integrity of capillary walls when se-
creted from metastatic breast cancer cells that have lodged in
the lungs. These results strongly suggest that Angptl4 acts as
an enhancer of breast cancer cell extravasation by transiently
suppressing the integrity of capillaries. These observations fit
with the role of Angptl4 as a vascular regulator in ischemia and
tumor hypoxia conditions (Le Jan et al., 2003) and are in line
with the role of the angiopoietin and angiopoietin-like factors in
vascular remodeling (Camenisch et al., 2002; Gale et al., 2002;
Parikh et al., 2006). Together with the presence of ANGPTL4 in
two distinct gene-expression signatures—the LMS and the
TBRS—that are associated with lung metastasis in breast can-
cer patients, this evidence suggests that Angptl4 is a clinically
relevant mediator of lung metastasis in breast cancer.
TGFb Activity in Primary Breast Tumors Is Linked
to Lung Metastasis
The role of TGFb in breast cancer progression has remained baf-
fling given the disparate results from various animal models. In
transgenic mouse models, TGFb action can enhance extravas-
cular lung metastasis formation (Siegel et al., 2003), whereas
a conditional knockout of TGFb receptor in themammary epithe-
lium showed that TGFb can suppress both primary tumor growthCell 133, 66–77, April 4, 2008 ª2008 Elsevier Inc. 73
Figure 6. Angptl4 Mediates Endothelial Monolayer Disruption, Lung Capillary Permeability, and Trans-Endothelial Tumor Cell Migration
(A) HUVEC monolayers were grown to confluence on fibronectin-coated slides and then treated for 24 hr with rhAngptl4. Slides were subsequently fluorescently
stained with anti-ZO-1 antibody, phalloidin, and anti-b-catenin antibody.
(B) HUVECmonolayers were treated for 24 hr with media conditioned by control LM2 cells or LM2 cells that overexpress Angptl4. Samples were stained for ZO-1
and phalloidin.
(C) GFP-labeledMDA-231 cells were injected via the tail vein and allowed to lodge in the lungs. One day post injection, a rhodamine-dextran dye was injected into
circulation. Three hours after dye injection, lungs were extracted and frozen sections were obtained. Representative confocal images are shown here of cells with
and without accumulation of dye in the lung parenchyma.
(D) Images were obtained as described in (C) with control or Angptl4-overexpressing MDA-MB-231 cells. A region of interest was drawn around the GFP-labeled
cells and the amount of dextran dye was quantified based on rhodamine emissions. n = 40 cells; error bars indicate SEM; p values calculated using the one-tailed
unpaired t test.
(E) Indicated cell lines were seeded into trans-well inserts that were previously covered with a HUVEC monolayer. Cells that migrated cross the endothelial layer
into the bottom side of the trans-well membrane were quantified with Volocity software. n = 15; error bars indicate SEM. P values calculated using the one-tailed
unpaired t test.
(F) Schematic model of the cytokine relay set up by TGFb activity in the primary tumor. ER primary tumor cells that are exposed to TGFb respond withANGPTL4
induction via the Smad pathway. As they enter the circulation and reach the lung capillaries, these cells secrete Angptl4, which disrupts endothelial cell junctions
thereby enabling the cancer cells to more efficiently enter the lung parenchyma.and lung metastases (Forrester et al., 2005). Therefore, the
causal relationship between TGFb and breast cancer progres-
sion in humans, and the identity of downstream TGFb targets
that may be involved in this action, has remained unknown.
To address this problem, we have developed a bioinformatic
classifier, theTBRS,basedon theTGFbgene-responsesignature
of human epithelial cells. The TBRS can not only classify tumor
tissue samples that have a gene-expression profile correspond-
ing to active TGFb signaling but can also help identify key down-
stream TGFbmediators, as shown in this work. Using this tool to
interrogate a wealth of existing clinical breast cancer data sets,
we have found that the presence of TGFb activity in primary
tumors is selectively associatedwith risk of lungmetastases. Sur-
prisingly, this association is restricted to ER tumors. Both ER+74 Cell 133, 66–77, April 4, 2008 ª2008 Elsevier Inc.and ER cancer cells exhibit ANGPTL4 induction by TGFb,
although the Angptl4 expression level is higher in TBRS+/ER
than in TBRS+/ER+ tumors. An explanation for the selective
association with lung metastasis in the ER group may lie with
the fact that the contributions of TGFb andANGPTL4 to lungme-
tastasis occur in the context of the LMS+ phenotype. The TBRS+
status is not associated with metastasis in either ER/LMS
tumors or in ER+ tumors, which are LMS (refer to Figure 1D).
ER tumors that score positive for both TBRS and LMS are the
ones with a high risk of lung metastasis (refer to Figure 1E).
We observed a high expression level of TGFb1, TGFb2, and
LTBP1 in TBRS+ tumors, which is consistent with the TGFb
activity typified by the TBRS and is in line with a reported associ-
ation of highTGFb1 levelswith lungmetastasis (Dalal et al., 1993).
Among ER tumors, a low expression of the TGFb type II recep-
tor is associated with favorable outcome (Buck et al., 2004). Our
data are also in line with these findings. Additionally, we find that
the Smad levels are differentially expressed with TBRS+ tumors
expressing higher levels of Smad3 and Smad4 while expressing
lower levels of Smad2. Indeed, Smad3,more than Smad2, is crit-
ical for the induction of TGFb gene responses (Chen et al., 2001,
2002; Gomis et al., 2006; Seoane et al., 2004). Despite these
interesting links, the TGFb pathway components tested individu-
ally or as a group did not perform as strongly as did the TBRS at
linking ER primary tumors with lung metastasis.
ATGFb-Angptl4 Relay SystemPrimesMammary Tumors
for Seeding of Lung Metastases
Several activities have been ascribed to TGFb that would favor
tumor progression in general, including the maintenance of
amesenchymal phenotype (Shipitsin et al., 2007) or the dampen-
ing of immune functions (Gorelik and Flavell, 2002). However, it is
not obvious how these effects of TGFbwould favor metastasis to
one particular organ over another. Yet, our clinical and functional
evidence selectively links TGFb in the primary breast tumor mi-
croenvironment to lung metastasis and not bone metastasis.
This observation implies a biologically selective mechanism,
and our results point atANGPTL4 induction by TGFb as a center-
piece of this mechanism. We provide evidence that TGFb stimu-
lation of mammary carcinoma cells before they enter the circula-
tion primes these cells for seeding of the lungs through
a transient induction of ANGPTL4. This effect is mediated by
the canonical TGFb receptor and Smad signaling pathway,
which in normal breast epithelial cells would suppress cell prolif-
eration, but in metastatic breast cancer cells fails to efficiently
trigger cytostatic gene responses (Gomis et al., 2006). Given
the disruptive effect of Angptl4 on endothelial cell junctions,
we suggest that TGFb-mediated induction of this factor in-
creases the extravasation capabilities of breast cancer cells as
they arrive in the lungs. Thus, a cytokine in themicroenvironment
of mammary tumors can endow departing cancer cells with in-
creased expression of another cytokine to more efficiently
seed a distant organ.
A vasculature disruptive mechanism may provide a selective
invasive advantage in lung but not bone because of the inherent
differences in the microvasculature of these two tissues. Lung
vascular endothelial junctions act as a barrier that restricts the
passage of cells. In contrast, the bone-marrow vasculature con-
sists of capillary vascular channels, called sinusoids, which have
a discontinuous endothelium to facilitate the passage of hemato-
poietic and other cells (Oghiso and Matsuoka, 1979). Therefore,
lungmetastasis may require robust extravasation functions such
as those provided by Angptl4 and other factors (Gupta et al.,
2007a), and additional lung-colonizing functions (Gupta et al.,
2007b). In contrast, osteolytic metastasis by breast cancer cells
may principally require their adaptation to the bone microenvi-
ronment and the recruitment and activation of osteoclasts
(Mundy, 2002).
The TGFb-Angptl4 cytokine relay system described here pro-
vides an example of how stimuli in the primary tumor can affect
distant metastases. We envision that TGFb and other factors in
different tumor microenvironments may act in this manner to in-fluence metastases from other tumor types, or to other organ
sites. The ability of TGFb to prime disseminating breast cancer
cells for lung metastasis is clinically and mechanistically distinct
from the advantage that metastatic colonies may later extract
from locally produced TGFb (Mundy, 2002). Indeed, of 67 sam-
ples of human breast cancermetastasis to bone, lung, brain liver,
and other sites that we analyzed, more than half scored as
TBRS+. This result is also consistent with our previous observa-
tion of activated Smad in a majority of bone metastases from
breast cancer patients (Kang et al., 2005) and the involvement
of several TGFb target genes in the bone osteolytic process
(Kang et al., 2003b; Mundy, 2002). However, TGFb metastatic
lesions might support subsequent rounds of metastatic dissem-
ination by themechanism outlined here, pointing at opportunities
for therapeutic intervention based on the present findings.
EXPERIMENTAL PROCEDURES
Additional methods can be found in the Supplemental Data.
Cell Culture and Reagents
MDA-MB-231 and its metastatic derivatives LM2-4175 and BoM-1833 have
been described previously (Kang et al., 2003b; Minn et al., 2005). Breast car-
cinoma cells were isolated from the pleural effusion of patients with metastatic
breast cancer treated at our institution upon written consent obtained follow-
ing IRB regulations as previously described (Gomis et al., 2006). BCN samples
were obtained and treated as per Hospital Clinic de Barcelona guidelines
(CEIC approved).
TGFb and TGFb-receptor inhibition used 100pM TGFb1 (R&D Systems) for
3 or 6 hr as indicated and 10 mM SB431542 (Tocris) with 24 hr pretreatment.
Epithelial cell lines were treated for 3 hr with BMP2 (25 ng/mL, R&D), Wnt3a
(50 ng/mL, R&D), FGF (5 ng/mL, Sigma), EGF (100 ng/mL, Invitrogen), IL6
(20 ng/mL, R&D), VEGF-165 (100 ng/mL, R&D), and IL1b (100 ng/mL, R&D).
Conditioned media experiments were performed by growing cells in serum-
deprived media for 48 hr. Recombinant human Angptl4 (Biovendor) was
used at 2.5 mg/mL for 24 hr.
TGFb-Response Gene-Expression Signature and TBRS Classifier
Cell lines with and without TGFb1 treatment (3 hr, 100 pM) were subject to
expression profiling using Affymetrix U133A or U133 plus2 microchips. Micro-
array results were preprocessed using RMA algorithm (carried with affy pack-
age of R statistical program). The first comparison was conducted between all
TGFb-treated samples versus all untreated samples. Three hundred and fifty
genes that yielded a p value of 0.05 or less (after Benjamini and Hochberg cor-
rection for multiple tests) were kept. Among these genes, we chose to focus on
the genes that are significantly changed in at least two different cell lines when
the cell lines are considered separately. This step resulted in 174 probe sets
corresponding to 153 distinct human genes, which were collectively desig-
nated as the TGFb gene-response signatures.
Animal Studies
All animal work was done in accordance with a protocol approved by the
MSKCC Institutional Animal Care andUse Committee. NOD/SCID femalemice
(NCI) age-matched between 5–7 weeks were used for xenografting studies.
For experimental metastasis assays from bilateral orthotopic inoculations,
the tumors were extracted from both mammary glands when they each
reached 300 mm3, approximately 30 days. Seven days after mastectomies,
lungmetastases weremonitored and quantified using noninvasive biolumines-
cence as previously described (Minn et al., 2005).
In Vivo Lung Permeability Assays
To observe in vivo permeability of lung blood vessels, tumor cells were labeled
by incubating with 5 mM cell tracker green (Invitrogen) for 30 min and inocu-
lated into the lateral tail vein. One day post inoculation, mice were injectedCell 133, 66–77, April 4, 2008 ª2008 Elsevier Inc. 75
intravenously with rhodamine-conjugated dextran (70 kDa, Invitrogen) at 2 mg
per 20 g body weight. After 3 hr, mice were sacrificed; lungs were extracted
and fixed by intratracheal injection of 5ml of 4%PFA. Lungs were fixed frozen,
and 10 mm sections were taken to be examined by fluorescence microscopy
for vascular leakage. Images were acquired on an AxioImager Z1 microscopy
system (Zeiss). To analyze, a uniform ROI of approximately 3 nuclei in diameter
was drawn around the tumor cells and applied to each image. A second larger
ROI was also applied with similar results. Signal from the ROI was quantified
using Volocity (Improvision).
Statistical Analysis
Results are reported as mean ± SEM unless otherwise noted. Comparisons
between continuous variables were performed using an unpaired one-sided
t test. Statistics for the orthotopic lung metastasis assays were performed
using log transformation of raw photon flux.
ACCESSION NUMBERS
The normalized data has been deposited in the Array Express database
(E-TABM-420).
SUPPLEMENTAL DATA
Supplemental data include nine figures, three tables, and Supplemental
Experimental Procedures and can be found with this article online at http://
www.cell.com/cgi/content/full/133/1/66/DC1/.
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